These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 36803349)
1. A comprehensive computational analysis to explore the importance of SIGLECs in HCC biology. Yao S; Chen W; Chen T; Zuo H; Bi Z; Zhang X; Pang L; Jing Y; Yin X; Cheng H BMC Gastroenterol; 2023 Feb; 23(1):42. PubMed ID: 36803349 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma. Chen J; Gao G; Zhang Y; Dai P; Huang Y BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471 [TBL] [Abstract][Full Text] [Related]
3. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. Jiang H; Ning G; Wang Y; Lv W Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187 [TBL] [Abstract][Full Text] [Related]
4. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma. Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238 [TBL] [Abstract][Full Text] [Related]
5. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis. Tang Y; Zhang Y; Hu X Biomed Res Int; 2020; 2020():4251761. PubMed ID: 33376723 [TBL] [Abstract][Full Text] [Related]
6. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma. Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K Front Immunol; 2023; 14():1202324. PubMed ID: 37457742 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma. Wu Z; Guo L; Wan L; Xu K; Luo L; Wen Z J Cancer Res Clin Oncol; 2023 Oct; 149(13):11891-11905. PubMed ID: 37410140 [TBL] [Abstract][Full Text] [Related]
8. DDR1 is a Novel Biomarker and Potential Therapeutic Target for the Combination Treatment of Liver Hepatocellular Carcinoma. Li T; Hu H; Song Y; Shi Y; Hu D; Shen W; Ning B Cancer Control; 2024; 31():10732748241286257. PubMed ID: 39284684 [TBL] [Abstract][Full Text] [Related]
9. Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes. Yan J; Cao J; Chen Z BMC Cancer; 2021 Feb; 21(1):175. PubMed ID: 33602168 [TBL] [Abstract][Full Text] [Related]
10. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma. Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596 [TBL] [Abstract][Full Text] [Related]
11. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107 [TBL] [Abstract][Full Text] [Related]
12. Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus. Ren X; Ji Y; Jiang X; Qi X Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30355653 [TBL] [Abstract][Full Text] [Related]
13. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma. Jiang X; Zhang W; Li L; Xie S Pathol Oncol Res; 2021; 27():1609985. PubMed ID: 34737677 [TBL] [Abstract][Full Text] [Related]
14. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma. Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z Front Immunol; 2021; 12():653836. PubMed ID: 33897701 [No Abstract] [Full Text] [Related]
15. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma. Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma. Lin H; Zhang R; Wu W; Lei L Cancer Genet; 2020 Jul; 245():27-34. PubMed ID: 32559715 [TBL] [Abstract][Full Text] [Related]
17. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma. Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595 [TBL] [Abstract][Full Text] [Related]
18. FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma. Tang X; Luo B; Huang S; Jiang J; Chen Y; Ren W; Shi X; Zhang W; Shi L; Zhong X; Lü M Eur J Med Res; 2023 Oct; 28(1):419. PubMed ID: 37821996 [TBL] [Abstract][Full Text] [Related]
19. Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC. Wu C; Qi X; Qiu Z; Deng G; Zhong L Aging (Albany NY); 2021 Sep; 13(18):22148-22163. PubMed ID: 34491228 [TBL] [Abstract][Full Text] [Related]
20. [CDK1, CCNB1 and NDC80 are associated with prognosis and progression of hepatitis B virus-associated hepatocellular carcinoma: a bioinformatic analysis]. Li Y; Wu D; Wei C; Yang X; Zhou S Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1509-1518. PubMed ID: 34755666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]